ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: PP11 • ACR Convergence 2022

    Exercise as a Supportive Treatment for My Ankylosing Spondylitis

    Sara King-Dowling, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are often caught in a paradox as they experience mobility challenges, but long periods of immobility cause increased…
  • Abstract Number: PP13 • ACR Convergence 2022

    How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health

    Tonya Hinton-Green, Philadelphia, PA

    Background/Purpose: My story begins in the ER where I was diagnosed with lupus right after my 22nd birthday.For the next 25 years I went from…
  • Abstract Number: PP10 • ACR Convergence 2022

    How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology

    Brooklyn Johnson1 and Kathleen Collins2, 1Memphis, TN, 2LeBonheur Children's Hospital, Memphis, TN

    Background/Purpose: The summer before my senior year, I developed a faint rash on my face and my arms. At a dermatology appointment, I pointed this…
  • Abstract Number: 2267 • ACR Convergence 2022

    Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 Interferons in Cutaneous Lupus

    Thomas Vazquez1, Nilesh Kodali1, DeAnna Diaz2, Jay Patel3, Emily Keyes2, Grant Sprow2, Meena Sharma1, Mariko Ogawa-Momohara2, Madison Grinnell2, Josh Dan2 and Victoria Werth2, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN

    Background/Purpose: Type 1 interferons (IFN-1) are major drivers of disease activity in systemic (SLE) and cutaneous lupus erythematosus (CLE). Plasmacytoid dendritic cells (pDCs) are the…
  • Abstract Number: PP17 • ACR Convergence 2022

    Engaging with the Spoon Theory: How I Make Decisions Using a Cost-Benefit Analysis That Works to Improve My Mental Health While Living with RA

    Stephanie Aleite, AiArthritis, St. Louis, MO

    Background/Purpose: Patients living with rheumatoid arthritis (RA) often also live with comorbid mental health conditions. Regardless of diagnosed mental health condition, living with a chronic…
  • Abstract Number: PP21 • ACR Convergence 2022

    What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work

    Shilpa Venkatachalam, Global Healthy Living Foundation, New York, NY

    Background/Purpose: When I first received my Rheumatoid Arthritis (RA) diagnosis 5 years ago, I experienced a combination of relief and disbelief. Relief because now all…
  • Abstract Number: PP19 • ACR Convergence 2022

    Living with Rheumatoid Arthritis in a Rural Farming Community: How I Found a Rheumatologist and Got Targeted Treatment

    Vanessa Kerr, Mexico, MO

    Background/Purpose: I'm Vanessa and I've been married to James, a farmer, for 27 years. We have 5 children and when my fourth was born, I…
  • Abstract Number: PP24 • ACR Convergence 2022

    Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp

    Kaye Anderson1, Kristine Carandang2 and Courtney Wells3, 1Young Patients' Autoimmune Research & Empowerment Alliance, River Falls, WI, 2Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 3University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN

    Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of ten. The constant battle between doctor appointments, pain, and medication side effects left…
  • Abstract Number: PP23 • ACR Convergence 2022

    The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient

    Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY

    Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
  • Abstract Number: PP26 • ACR Convergence 2022

    Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life

    Catherine Ames1, Courtney Wells2 and Kristine Carandang1, 1Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 2University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN

    Background/Purpose: What if Carrie Bradshaw, sex advice columnist, fashionsta, and all around icon from Sex and the City were chronically ill? Or disabled? That's the…
  • Abstract Number: PP25 • ACR Convergence 2022

    From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective

    Shung Chiu1 and Mei Nee Chiu2, 1Spondylitis Association of America, Ludhiana, Punjab, India, 2University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India

    Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
  • Abstract Number: PP15 • ACR Convergence 2022

    Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic

    Laura Genoves, Arthritis Foundation, Bainbridge Island, WA

    Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
  • Abstract Number: 2266 • ACR Convergence 2022

    Platelet-selectin Prime Lupus Neutrophils to Produce Mitochondrial ROS and Participate in SLE Pathogenesis

    Marc Scherlinger1, Pierre Vacher2, Vivien Guillotin3, Isabelle Douchet4, Christophe Richez5 and Patrick Blanco4, 1BIDMC Harvard University, Boston, MA, 2INSERM U1218, Bordeaux, France, 3CHU de Bordeaux, Bordeaux, France, 4UMR-CNRS 5164 Immunoconcept, Bordeaux, France, 5CHRU Bordeaux, Bordeaux, France

    Background/Purpose: In patients with active systemic lupus erythematosus (SLE), circulating platelets have an activated phenotype characterized by the expression of P-selectin (CD62P). We have shown…
  • Abstract Number: 2217 • ACR Convergence 2022

    Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity

    Amir Razmjou1, Jennifer Wang1, Ani Shahbazian1, Jeffrey Curtis2, Dimitrios Pappas3, Joel Kremer4 and Christina Charles-Schoeman5, 1UCLA Medical Center, Los Angeles, CA, 2University of Alabama at Birmingham, Hoover, AL, 3CorEvitas, LLC, Waltham, MA, 4The Corrona Research Foundation, Delray Beach, FL, 5Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA

    Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with paraoxonase, lactonase, and arylesterase activities (1). PON1 is integral to the anti-inflammatory, anti-atherogenic functions of…
  • Abstract Number: 2026 • ACR Convergence 2022

    Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome

    Shruti Singh Kakan1, Yaping Ju2, Maria Edman2 and Sarah Hamm-Alvarez3, 1Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California; Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, 2Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, 3Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California; Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA

    Background/Purpose: Sjögren's Syndrome (SS) is an autoimmune disease characterized by infiltration of lymphocytes into lacrimal (LG) and salivary (SG) glands and their concurrent loss of…
  • « Previous Page
  • 1
  • …
  • 691
  • 692
  • 693
  • 694
  • 695
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology